| NAV | $7.41 | Daily Change | $0.15 | 2.07% |
| Market Price | $7.34 | Daily Change | $0.14 | 1.94% |
The China biotech market was valued at nearly $40bn in 2021. Forecasts suggest it could surpass $100bn by 2026, highlighting the substantial room for growth.1
Health care expenditures in China have grown at an annualized rate of 20% since 2003.2 We believe biotech companies are well-positioned to benefit from further growth in this sector.
In contrast to other funds that offer global or broader health care sector exposure, CHB specifically targets the biotech industry in China.
1Research and Markets, Oct 2022
2Council on Foreign Relations, May 2021
| Inception Date | 09/22/20 |
| Total Expense Ratio | 0.65% |
| Net Assets | $2.00 million |
| NAV | $7.41 |
| Fact Sheet | View the document |
The Global X China Biotech Innovation ETF (CHB) seeks to invest in companies that are directly involved in China’s biotechnology industry.
The Global X China Biotech Innovation ETF (CHB) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index.
| Ticker | CHB |
| Bloomberg Index Ticker | SOLCHB |
| CUSIP | 37954Y251 |
| ISIN | US37954Y2515 |
| Primary Exchange | Nasdaq |
| Shares Outstanding | 270,000 |
| Number of Holdings | 40 |
| 30-Day Median Bid-Ask Spread | 1.09% |
| 30-Day SEC Yield | 0.74% |
| Distribution Frequency | Semi-Annually |
| NAV | $7.41 | Daily Change | $0.15 | 2.07% |
| Market Price | $7.34 | Daily Change | $0.14 | 1.94% |
|
As of recent (06/30/23)
As of recent (06/30/23)
|
Fund NAV | Market Price | Index |
|---|---|---|---|
| 1 Year | -31.15% | -31.82% | -30.72% |
| Since Inception | -21.52% | -21.45% | -20.99% |
| 1 Year | -27.09% | -25.39% | -26.55% |
| Since Inception | -21.82% | -21.53% | -21.27% |
| Year-to-Date | -19.65% | -18.07% | -19.36% |
| 1 Month | -6.13% | -5.65% | -6.14% |
| 3 Months | -15.69% | -14.63% | -15.56% |
| Since Inception | -48.90% | -48.76% | -47.93% |
| Year-to-Date | -23.74% | -21.59% | -23.34% |
| 1 Month | -8.78% | -7.55% | -8.64% |
| 3 Months | -10.91% | -9.71% | -10.78% |
| Since Inception | -51.50% | -50.96% | -50.50% |
Performance is shown on a total return basis (i.e., with gross income reinvested, where applicable). Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated.
| Net Assets (%) | Ticker | Name | SEDOL | Market Price ($) | Shares Held | Market Value ($) |
|---|---|---|---|---|---|---|
| 8.85 | 2269 HK | WUXI BIOLOGICS CAYMAN INC | BL6B9P1 | 5.45 | 32,450 | 176,960.77 |
| 8.38 | 300122 C2 | CHONGQING ZHIF-A | BD5CJY8 | 6.72 | 24,950 | 167,661.26 |
| 7.81 | 000661 C2 | CHANGCHUN HIGH-A | BD5CDB3 | 18.64 | 8,377 | 156,121.91 |
| 7.11 | 1093 HK | CSPC PHARMACEUTI | 6191997 | 0.74 | 192,300 | 142,118.43 |
| 6.91 | 300142 C2 | WALVAX BIOTECHNOLOGY CO-A | BD5CG36 | 3.29 | 42,000 | 138,210.72 |
| 4.89 | 002252 C2 | SHANGHAI RAAS -A | BD5CPJ5 | 0.95 | 103,100 | 97,783.38 |
| 4.87 | 600161 C1 | BEIJING TIAN-A | BP3R9J4 | 3.43 | 28,400 | 97,465.96 |
| 4.75 | 002422 C2 | SICHUAN KELUN-A | BD5CL08 | 3.85 | 24,700 | 95,059.24 |
| 4.53 | 002007 C2 | HUALAN BIOLOGI-A | BD5CL19 | 2.98 | 30,400 | 90,580.23 |
| 3.85 | ZLAB | ZAI LAB LTD-ADR | BD9GVY0 | 24.47 | 3,143 | 76,909.21 |
| 3.77 | 1548 HK | GENSCRIPT BIOTECH CORP | BD9Q2J2 | 2.52 | 29,850 | 75,341.58 |
| 3.56 | 300601 C2 | SHENZHEN KANGT-A | BFY8HT2 | 3.92 | 18,193 | 71,238.51 |
| 2.56 | 1530 HK | 3SBIO INC | BY9D3L9 | 0.86 | 59,500 | 51,124.55 |
| 2.39 | 300676 C2 | BGI GENOMICS CO LTD-A | BFY8H58 | 7.32 | 6,538 | 47,859.46 |
| 2.34 | 603392 C1 | BEIJING WANTAI-A | BMXTWX4 | 6.68 | 7,021 | 46,872.42 |
| 2.12 | 002030 C2 | DAAN GENE CO LTD-A | BD5CKW3 | 1.35 | 31,380 | 42,320.26 |
| 2.11 | 688639 C1 | ANHUI HUAHENG BI | BNHPNZ4 | 13.75 | 3,073 | 42,258.75 |
| 1.69 | 603127 C1 | JOINN LABORATO-A | BK94819 | 3.22 | 10,506 | 33,865.58 |
| 1.48 | 000403 C2 | PACIFIC SHUANG-A | BMQ8TB5 | 2.77 | 10,700 | 29,594.11 |
| 1.42 | 300482 C2 | GUANGZHOU WOND-A | BFY8GZ1 | 3.45 | 8,200 | 28,298.92 |
| 1.37 | 688739 C1 | LIAONING CHENGDA | BNHPPJ2 | 4.65 | 5,878 | 27,342.72 |
| 1.31 | 002038 C2 | BEIJING SL -A | BD5CJD7 | 1.28 | 20,500 | 26,242.25 |
| 1.26 | 600195 C1 | CHINA ANIMAL HUSBANDRY-A | BP3RFX0 | 1.54 | 16,300 | 25,155.11 |
| 1.12 | 300255 C2 | HEBEI CHANGSHA-A | BD5LWT1 | 1.27 | 17,600 | 22,312.83 |
| 1.04 | 688185 C1 | CANSINO BIOLOGICS INC-A | BMD9JD3 | 10.47 | 1,981 | 20,735.17 |
| 0.98 | 300841 C2 | CHENGDU KANGHU-A | BMXVCN0 | 9.09 | 2,150 | 19,536.75 |
| 0.97 | 6855 HK | ASCENTAGE PHARMA | BK9PZW2 | 2.77 | 7,000 | 19,422.32 |
| 0.78 | 9966 HK | ALPHAMAB ONCOLOGY | BL6WGG4 | 1.20 | 13,100 | 15,661.24 |
| 0.70 | 688278 C1 | XIAMEN AMOYTOP B | BNHPMR9 | 4.61 | 3,049 | 14,053.50 |
| 0.66 | 603387 C1 | GETEIN BIOTECH INC-A | BFB4S90 | 1.54 | 8,520 | 13,160.24 |
| 0.66 | 688319 C1 | CHENGDU OLYMVAX | BNHPMZ7 | 2.36 | 5,567 | 13,123.51 |
| 0.61 | 688317 C1 | SHANGHAI ZJ BI-A | BQ3RXD3 | 3.16 | 3,845 | 12,146.96 |
| 0.49 | 300318 C2 | BEIJING BOHUI -A | BMQBTF8 | 0.77 | 12,700 | 9,747.47 |
| 0.47 | 688526 C1 | WUHAN KEQIAN B-A | BQ3RXJ9 | 2.73 | 3,460 | 9,436.90 |
| 0.46 | 688105 C1 | NANJING VAZYME B | BNHNC28 | 3.88 | 2,379 | 9,237.22 |
| 0.45 | 301207 C2 | HUALAN BIOLOGI-A | BLC7YJ2 | 4.36 | 2,050 | 8,943.16 |
| 0.38 | 002880 C2 | SHENZHEN WEIGU-A | BMTCVX0 | 4.81 | 1,600 | 7,688.33 |
| 0.32 | 688221 C1 | FRONTIER BIOTECH | BNHPM57 | 1.46 | 4,399 | 6,414.99 |
| 0.22 | 1167 HK | JACOBIO PHARMACE | BMQC6Q1 | 0.42 | 10,500 | 4,376.73 |
| 0.19 | 9939 HK | KINTOR PHARMACEUTICAL LTD | BMDWVN6 | 0.36 | 10,300 | 3,740.23 |
| 0.13 | OTHER PAYABLE & RECEIVABLES | 1.00 | 2,557 | 2,557.08 | ||
| 0.07 | CASH | 1.00 | 1,346 | 1,346.02 |
| Industry | Weight (%) | |
|---|---|---|
| Biotechnology | 81.2 | |
| Pharmaceuticals: Other | 8.3 | |
| Pharmaceuticals: Generic | 7.9 | |
| Medical Specialties | 1.5 | |
| Pharmaceuticals: Major | 1.1 |
All Sector, Industry and Geographic breakdowns, where provided, are based on equity positions held by the ETF and exclude cash, currencies, and other holdings.
Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified.
Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.
Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.
Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.
Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.